Breakthrough in Flu Vaccine Development: FDA Panel Votes in Favor of New mRNA-Based Shot In a significant step forward for public health, a groundbreaking flu vaccine has moved closer to becoming available to the general public after a unanimous vote by an FDA advisory panel. Moderna's mRNA-based vaccine, known as mFlusiva, has been recommended for approval in adults aged 50-64 and those 65 and older, with the panel concluding that its benefits far outweigh the risks. The innovative vaccine uses a novel mRNA technology to stimulate the body's immune response, offering a potentially more effective and safer alternative to traditional flu shots. If approved, mFlusiva could provide enhanced protection against seasonal flu, particularly for vulnerable populations, and mark a major milestone in the fight against infectious diseases.
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s mRNA-based vaccine for approval. The FDA’s independent vaccine advisors voted unanimously 9-0 that the benefits outweigh the risks for Moderna’s mFlusiva shot in people ages 50 to 64 as well as 65 and older. Moderna is seeking...
